News | November 06, 2007

Stem Cells Injected Into Heart Boost Pumping Ability After Heart Attack

November 7, 2007 - Patients’ own stem cells injected into their hearts after treatment for an ST elevation heart attack improved their hearts’ improved pumping ability, researchers reported during a late-breaking special session on stem cell research at the American Heart Association Scientific Sessions 2007.

In the IM-BMC randomized, double-blind trial, researchers assessed the safety and efficacy of injecting sufferers’ own stem cells into their hearts. The patients had been initially treated with clot-busting drugs, followed by percutaneous coronary intervention (PCI).

Past studies have yielded mixed results regarding the effect of injecting patients’ own bone marrow cells to treat reduced heart function, irregular heartbeat and re-blockages in stented arteries.

Researchers enrolled 80 patients who had had an ST elevation heart attack and they were randomly selected to receive intracoronary bone marrow or placebo injections in the heart or placebo injections. These procedures were performed 0-3 days after bone marrow cell (BMC) delivery and repeated six months after the STEMI.

At six months, the patients randomized to BMC therapy (n=33) showed a significant increase of their global ejection fraction (EF) measured by angiography (from 59±8% to 67±9, p

Researchers observed no differences between the groups in the measures of heart rate variability, signal-averaged electrocardiogram, prevalence of positive T-wave alternans tests, or the minimal lumen diameter and area of the stented culprit lesion.

“This study shows intracoronary BMC-therapy is associated with an improvement of global left ventricular function and no adverse effects on arrhythmia risk profile or restenosis of the stented coronary lesions in patients treated with thrombolytic therapy followed by PCI of an acute ST elevation heart attack,” said Heikki Huikuri, M.D., lead investigator and professor of medicine and director of cardiology sector at the University of Oulu Hospital in Oulu, Finland.

Support for this study was provided by the Finnish Academy of Science, Helsinki, Finland and Boston Scientific Inc.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The American Heart Association makes no representation or warranty as to their accuracy or reliability.

For more information:

Related Content

Placental Stem Cells Can Regenerate the Heart After Heart Attack
News | Stem Cell Therapies | May 20, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from the placenta...
ProxiCor Extracellular Matrix Reduces Complications, Readmissions Following Pericardial Reconstruction
News | Stem Cell Therapies | April 19, 2019
Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the Journal of...
FDA Releases Final Guidances on Regenerative Medicine Therapies
News | Stem Cell Therapies | March 04, 2019
The U.S. Food and Drug Administration (FDA) recently finalized two guidance documents regarding regenerative medicine...
Heart Muscle Cells Created From Stem Cells Beat in Sync
News | Stem Cell Therapies | February 01, 2019
A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts heal themselves – a...
FDA Clamps Down on Unapproved Stem Cell Therapies
News | Stem Cell Therapies | December 20, 2018
December 20, 2018 — The U.S.
Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies | October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies | September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies | August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Overlay Init